CEO Cuong Do on BioVie's (Nasdaq: BIVI) $10B+ Drug Candidate & Two Imminent Readouts
May. 27, 2026
CEO Cuong Do joins RedChip to discuss BioVie (Nasdaq: BIVI), a clinical-stage biopharmaceutical company advancing a first-in-class pipeline targeting Parkinson's disease, Long COVID, Alzheimer's, and refractory ascites.
BioVie's lead asset, bezisterim (NE3107), is an orally available small molecule that targets two critical and underaddressed drivers of neurodegeneration — TNFα-driven inflammation and insulin resistance. Unlike existing therapies that focus narrowly on dopamine or symptom management, bezisterim is designed to address the underlying biological mechanisms shared across multiple age-related diseases, positioning it as a potential platform therapy with multi-billion-dollar market reach.
With two imminent binary catalysts, a cash-rich balance sheet, and multi-billion-dollar market opportunities across four indications, BioVie offers investors a differentiated risk/reward profile at the intersection of neurodegeneration and longevity science.
